论文部分内容阅读
目的对原发性高脂血症患者采用阿托伐他汀和辛伐他汀治疗的临床疗效进行对比研究。方法此次研究抽取102例原发性高脂血症患者,按随机数字表法分为两组,每组各51例;对照组患者采用辛伐他汀治疗,观察组患者采用阿托伐他汀治疗,对两组患者的临床治疗效果进行对比评估。结果观察组治疗总有效率为96.08%,高于对照组(80.39%,P<0.05)。治疗前两组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)四项血脂指标水平比较差异未见统计学意义(P>0.05);治疗后,观察组患者上述四项血脂指标水平改善均显著优于对照组(P<0.05)。观察组不良反应发生率为3.92%,与对照组(5.88%)相比差异未见统计学意义(P>0.05)。结论原发性高脂血症患者采用阿托伐他汀治疗效果显著优于辛伐他汀,疗效更佳,降脂效果更优,可促进患者生活质量的改善;因此,值得在临床中推广及采用。
Objective To compare the clinical efficacy of atorvastatin and simvastatin in patients with primary hyperlipidemia. Methods A total of 102 patients with primary hyperlipidemia were randomly divided into two groups (n = 51 in each group). Patients in the control group received simvastatin and those in the observation group received atorvastatin , The clinical efficacy of two groups of patients for comparative assessment. Results The total effective rate of the observation group was 96.08%, higher than that of the control group (80.39%, P <0.05). The levels of TC, TG, LDL-C and HDL-C in the two groups before treatment had no significant difference (P > 0.05). After treatment, the improvement of the above four blood lipid indicators in the observation group was significantly better than that in the control group (P <0.05). The incidence of adverse reactions in the observation group was 3.92%, which was not significantly different from that in the control group (5.88%) (P> 0.05). Conclusion Atorvastatin is superior to simvastatin in patients with primary hyperlipidemia, with better efficacy and better lipid-lowering effect, which can improve the quality of life of patients. Therefore, it is worth to be popularized and adopted in clinic .